A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis

C. Salvarani; P. Macchioni; I. Olivieri; A. Marchesoni; M. Cutolo; G. Ferraccioli; F. Cantini; F. Salaffi; A. Padula; C. Lovino; L. Dovigo; G. Bordin; C. Davoli; G. Pasero; O. D C Alberighi

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis

C. Salvarani, P. Macchioni, I. Olivieri, A. Marchesoni, M. Cutolo, G. Ferraccioli, F. Cantini, F. Salaffi, A. Padula, C. Lovino, L. Dovigo, G. Bordin, C. Davoli, G. Pasero, O. D C Alberighi

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Abstract

Objective. To compare the efficacy and tolerability of cyclosporine (CSA) with that of symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA). Methods. Twelve rheumatology centers recruited 99 patients with active PsA in a 24 week, prospective, randomized, open, controlled study. The patients were treated with CSA (3 mg/kg/day) or SSZ (2000 mg/day) plus ST, or ST alone (nonsteroidal antiinflammatory drugs, analgesics, and/or prednisone≤5 mg/day). The primary endpoint was the 6 month change in pain. Analyses were on the basis of the intention-to-treat principle. Results. In comparison with both SSZ and ST, there was a statistically significant difference in favor of CSA in terms of the mean changes in the pain score (p

Original language	English
Pages (from-to)	2274-2282
Number of pages	9
Journal	Journal of Rheumatology
Volume	28
Issue number	10
Publication status	Published - 2001

Keywords

Low dose cyclosporine
Psoriatic arthritis
Sulfasalazine
Symptomatic therapy

ASJC Scopus subject areas

Rheumatology
Immunology

Cite this

Salvarani, C., Macchioni, P., Olivieri, I., Marchesoni, A., Cutolo, M., Ferraccioli, G., Cantini, F., Salaffi, F., Padula, A., Lovino, C., Dovigo, L., Bordin, G., Davoli, C., Pasero, G., & Alberighi, O. D. C. (2001). A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. Journal of Rheumatology, 28(10), 2274-2282.

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. / Salvarani, C.; Macchioni, P.; Olivieri, I.; Marchesoni, A.; Cutolo, M.; Ferraccioli, G.; Cantini, F.; Salaffi, F.; Padula, A.; Lovino, C.; Dovigo, L.; Bordin, G.; Davoli, C.; Pasero, G.; Alberighi, O. D C.

In: Journal of Rheumatology, Vol. 28, No. 10, 2001, p. 2274-2282.

Research output: Contribution to journal › Article › peer-review

Salvarani, C. ; Macchioni, P. ; Olivieri, I. ; Marchesoni, A. ; Cutolo, M. ; Ferraccioli, G. ; Cantini, F. ; Salaffi, F. ; Padula, A. ; Lovino, C. ; Dovigo, L. ; Bordin, G. ; Davoli, C. ; Pasero, G. ; Alberighi, O. D C. / A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. In: Journal of Rheumatology. 2001 ; Vol. 28, No. 10. pp. 2274-2282.

@article{36a988ffcb0d4d23abaa5e667ced2f34,

title = "A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis",

abstract = "Objective. To compare the efficacy and tolerability of cyclosporine (CSA) with that of symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA). Methods. Twelve rheumatology centers recruited 99 patients with active PsA in a 24 week, prospective, randomized, open, controlled study. The patients were treated with CSA (3 mg/kg/day) or SSZ (2000 mg/day) plus ST, or ST alone (nonsteroidal antiinflammatory drugs, analgesics, and/or prednisone≤5 mg/day). The primary endpoint was the 6 month change in pain. Analyses were on the basis of the intention-to-treat principle. Results. In comparison with both SSZ and ST, there was a statistically significant difference in favor of CSA in terms of the mean changes in the pain score (p",

keywords = "Low dose cyclosporine, Psoriatic arthritis, Sulfasalazine, Symptomatic therapy",

author = "C. Salvarani and P. Macchioni and I. Olivieri and A. Marchesoni and M. Cutolo and G. Ferraccioli and F. Cantini and F. Salaffi and A. Padula and C. Lovino and L. Dovigo and G. Bordin and C. Davoli and G. Pasero and Alberighi, {O. D C}",

year = "2001",

language = "English",

volume = "28",

pages = "2274--2282",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "10",

}

TY - JOUR

T1 - A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis

AU - Salvarani, C.

AU - Macchioni, P.

AU - Olivieri, I.

AU - Marchesoni, A.

AU - Cutolo, M.

AU - Ferraccioli, G.

AU - Cantini, F.

AU - Salaffi, F.

AU - Padula, A.

AU - Lovino, C.

AU - Dovigo, L.

AU - Bordin, G.

AU - Davoli, C.

AU - Pasero, G.

AU - Alberighi, O. D C

PY - 2001

Y1 - 2001

N2 - Objective. To compare the efficacy and tolerability of cyclosporine (CSA) with that of symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA). Methods. Twelve rheumatology centers recruited 99 patients with active PsA in a 24 week, prospective, randomized, open, controlled study. The patients were treated with CSA (3 mg/kg/day) or SSZ (2000 mg/day) plus ST, or ST alone (nonsteroidal antiinflammatory drugs, analgesics, and/or prednisone≤5 mg/day). The primary endpoint was the 6 month change in pain. Analyses were on the basis of the intention-to-treat principle. Results. In comparison with both SSZ and ST, there was a statistically significant difference in favor of CSA in terms of the mean changes in the pain score (p

AB - Objective. To compare the efficacy and tolerability of cyclosporine (CSA) with that of symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA). Methods. Twelve rheumatology centers recruited 99 patients with active PsA in a 24 week, prospective, randomized, open, controlled study. The patients were treated with CSA (3 mg/kg/day) or SSZ (2000 mg/day) plus ST, or ST alone (nonsteroidal antiinflammatory drugs, analgesics, and/or prednisone≤5 mg/day). The primary endpoint was the 6 month change in pain. Analyses were on the basis of the intention-to-treat principle. Results. In comparison with both SSZ and ST, there was a statistically significant difference in favor of CSA in terms of the mean changes in the pain score (p

KW - Low dose cyclosporine

KW - Psoriatic arthritis

KW - Sulfasalazine

KW - Symptomatic therapy

UR - http://www.scopus.com/inward/record.url?scp=0034790695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034790695&partnerID=8YFLogxK

M3 - Article

C2 - 11669169

AN - SCOPUS:0034790695

VL - 28

SP - 2274

EP - 2282

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this